Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Infliximab dose optimization in moderate to severe plaque psoriasis
2008-000454-12Phase 3Completed
- Sponsor
- Schering AG
- Start
- Nov 2008
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in plaque psoriasis comparing Infliximab every 6 weeks with Infliximab every 8 weeks plus methotrexate (2 arms). Primary endpoint: PASI-75 response rate at Week 28. Started Nov 2008; status: completed.
02
Drugs
infliximabmethotrexate
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on 2008-000454-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000454-12.